GSK’s Exdensur requires just two injections a year to treat severe asthma. Less frequent injections give this new biologic medicine a dosing edge over one of GSK’s own blockbuster respiratory products as well as severe asthma drugs from companies such as AstraZeneca, Sanofi, and Amgen.
GSK submitted the same Blenrep clinical trial data to global regulators and the FDA, but received a slightly more limited regulatory approval in the U.S. In an interview during the annual meeting of the American Society of Hematology, GSK oncology executive Hesham Abdullah explained what else the FDA wants from Blenrep clinical trials.
AI-native tax firm Gelt combines top human tax experts with AI to help physicians and healthcare practices use data-driven tax strategies to lower liabilities, improve profitability, and future-proof their finances.
GSK paid $85 million up front for global rights to a small-interfering RNA therapy discovered and developed by startup Empirico. The pharmaceutical giant said this drug candidate could be used as a monotherapy and as part of drug combinations for treating COPD and other inflammatory respiratory diseases.
GSK drug Blenrep, which exited the market in 2022 after failing a confirmatory study, now has a new FDA approval as a third-line multiple myeloma treatment. The U.S. regulatory decision is more limited than the recent European approval for the blood cancer drug.
President Trump has been pursuing policies intended to entice drugmakers to bring manufacturing and jobs to the U.S. GSK’s announcement makes it the latest big pharma company to unveil a multi-billion dollar plan for new U.S. facilities.
The deal helps move BioNTech’s proposed acquisition of CureVac closer to completion. With the settlement, GSK said it will tender the CureVac shares it owns in support of the $1.25 billion acquisition.
Alan Murray on improving access for medical transportation.
GSK drug Nucala has expanded its FDA-approved uses to include maintenance treatment of chronic obstructive pulmonary disease that’s driven by eosinophils, a type of immune cell. The antibody drug will compete against the blockbuster Sanofi product Dupixent, which expanded its FDA approval to COPD last year.
GSK is acquiring Boston Pharmaceuticals’ efimosfermin, which posted Phase 2 results showing improvement in fibrosis and resolution of MASH. GSK said this fusion protein will complement an siRNA drug it is currently developing for liver diseases.
Solu Therapeutics’ platform technology, which was licensed from GSK, pairs a small molecule with an antibody to address elusive disease targets. Cancer is Solu’s initial focus, but the startup is also exploring applications of its platform to immunology.
GSK is licensing an ABL Bio technology that yields bispecific antibodies engineered to leverage a certain transmembrane receptor to cross the blood-brain barrier to treat neurodegeneration. GSK is already partnered with Alector, which has monoclonal antibodies in clinical development for Alzheimer’s disease.
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
The FDA approved GSK antibiotic Blujepa as a treatment for uncomplicated urinary tract infections. The drug’s novel mechanism of action addresses a broader range of pathogens and could offer a way to lower the potential for drug resistance.
Infectious disease is the focus of the biopharma track at INVEST Pitch Perfect May 20-21 in Chicago. Register today!
Ouro Medicines’ drugs deplete disease-driving immune cells, allowing the immune system to reset with naïve cells that don’t attack the body. Monograph Capital founded the startup in partnership with GSK.
Results from the Phase 3 DREAMM-7 study show GSK drug Blenrep is helping multiple myeloma patients live longer compared to treatment with blockbuster Johnson & Johnson drug Darzalex. The data, presented Monday during the annual meeting of the American Society of Hematology, are part of a submission now under FDA review that could lead to Blenrep’s return to the market.
Vesalius Therapeutics’ AI-based technology finds novel targets and intervention points for subgroups of patients within a common disease. A small molecule that Vesalius has been developing for a novel Parkinson’s disease target is now headed to GSK, which has licensed global rights.